What We Know from the Latest PEPFAR Data: Analysis of FY 2025 Quarter 4 Results
This analysis examines the latest Monitoring, Evaluation, and Results (MER) data released by the PEPFAR…
What We Know from the Latest PEPFAR Data: Analysis of FY 2025 Quarter 4 Results
This analysis examines the latest Monitoring, Evaluation, and Results (MER) data released by the PEPFAR program, the first glimpse of PEPFAR programming and outcomes for FY 2025.
MedCity Pivot Podcast: Modernizing Prior Auth
[Sponsored] In this episode, MedCity News’ Arundhati Parmar chats with a pharmacy benefits leader and a virtual pharmacy operator about ways to modernize and scale prior authorization. The post MedCity Pivot Podcast: Modernizing Prior Auth appeared first on MedCity News.
Adrian Owen & Faraz Shafaghi, Creyos
I spoke with neuroscientist Adrian Owen, co-founder and Chief Scientific Officer & Faraz Shafaghi, Chief Product Officer, at neurological testing company Creyos (which rhymes with “chaos”). Their cognitive assessment platform gives a baseline of neurological function and is essentially getting objective data at a point of care. This can now be done as part of…
Are Health Insurance Companies the Reason for Our Health System’s Ills?
In this JAMA Health Forum column, KFF’s Larry Levitt examines the criticism that health insurance companies are facing from political leaders, and explores the industry’s role in both causing and addressing some of the health systems’ biggest problems, including rising costs and prior authorization review.
Why Quality Shareback is the Missing Fuel for the Healthcare Interoperability Engine
The question is no longer whether shareback matters. It is whether the healthcare ecosystem is willing to prioritize it in practice by recognizing it in policy measurement, monitoring, and enforcement, as well as investing in the technical and governance structures needed to make shareback routine, high-quality, measurable, and reportable. The post Why Quality Shareback is…
The Healthcare Industry Has a Last Mile Problem — It Hasn’t Realized It Yet
Healthcare has solved for the hard part. The science, the surgery, the diagnosis: by global standards, we’re exceptional. What we haven’t solved for is what happens when the patient goes home. The post The Healthcare Industry Has a Last Mile Problem — It Hasn’t Realized It Yet appeared first on MedCity News.
Companies Expand AI Health Offerings, Even as Accuracy Questions Remain — The Monitor
Five technology companies have launched dedicated consumer-facing AI health tools so far in 2026, reflecting though questions about AI’s reliability remain. And a decades-old WHO classification has been misrepresented online to suggest that hormonal birth control pills were recently found to cause cancer.
How are payers and providers using AI? And why isn’t AI reducing administrative cost?
The Peterson Health Technology Institute (PHTI) recently released a report titled: “Administrative AI: Current Use and Potential Impact.” The report was based on a workshop PHTI convened with senior leaders from health systems, health plans, technology developers, investment firms, and federal agencies in order to discuss how technology and policy can enable AI to reduce…
How the DOJ Is Tackling Fraud in the ACA Marketplace
At the Medicarians Conference, Ricardo Carcas, assistant special agent in charge of the Office of Investigations, discussed cases of fraud in the ACA and how the DOJ is combatting it. The post How the DOJ Is Tackling Fraud in the ACA Marketplace appeared first on MedCity News.
FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral
Merck’s HIV drug Idvynso could become a drug choice for patients who need to switch from Gilead Sciences’ Biktarvy for safety or tolerability reasons. The Merck combination drug pairs two molecules that bring different mechanisms of action to suppressing HIV. The post FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral…
